Q4 2020 13F Holders as of 31 Dec 2020
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
6,138,804
-
Number of holders
-
25
-
Total 13F shares, excl. options
-
1,190,165
-
Shares change
-
+364,465
-
Total reported value, excl. options
-
$3,581,482
-
Value change
-
+$1,037,309
-
Put/Call ratio
-
2.41%
-
Number of buys
-
17
-
Number of sells
-
-5
-
Price
-
$3.01
Significant Holders of QUALIGEN THERAPEUTICS, INC. - Common Stock, par value $0.001 per share (QLGN) as of Q4 2020
30 filings reported holding QLGN - QUALIGEN THERAPEUTICS, INC. - Common Stock, par value $0.001 per share as of Q4 2020.
QUALIGEN THERAPEUTICS, INC. - Common Stock, par value $0.001 per share (QLGN) has 25 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 1,190,165 shares
of 6,138,804 outstanding shares and own 19.39% of the company stock.
Largest 10 shareholders include BlackRock Inc. (317,818 shares), VANGUARD GROUP INC (301,195 shares), GEODE CAPITAL MANAGEMENT, LLC (123,035 shares), QS Investors, LLC (82,000 shares), SUSQUEHANNA FUNDAMENTAL INVESTMENTS, LLC (62,500 shares), CITADEL ADVISORS LLC (45,928 shares), Cetera Investment Advisers (40,275 shares), NORTHERN TRUST CORP (38,731 shares), WEDBUSH SECURITIES INC (32,228 shares), and WELLS FARGO & COMPANY/MN (30,533 shares).
This table shows the top 25 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.